CDC25A (Ab-76) Antibody

What is CDC25A and what is its biological significance?

CDC25A is a dual-specificity phosphatase that functions as a critical regulator of cell cycle progression. It catalyzes the dephosphorylation of the Cdk/Cyc protein complexes, particularly activating CDK2/cyclin E and cyclin A complexes to control the G1/S transition. Additionally, CDC25A activates CDK1/cyclin B, which facilitates the transition into mitosis . As a dosage-dependent inducer of mitotic progression, CDC25A directly dephosphorylates CDC2 (CDK1) and stimulates its kinase activity, while also dephosphorylating CDK2 in complex with cyclin E in vitro . CDC25A is one of three CDC25 phosphatases in human cells (along with CDC25B and CDC25C) that share 20-25% amino acid identity in their N-terminal domains and 60% similarity in their C-terminal domains . The critical role of CDC25A in cell cycle regulation makes it an important target for research related to cancer and cellular proliferation control mechanisms.

What is the CDC25A (Ab-76) Antibody specifically designed to recognize?

The CDC25A (Ab-76) Antibody is a polyclonal antibody raised in rabbits, specifically designed to recognize the peptide sequence around amino acids 73-77 (M-G-S-S-E) derived from human CDC25A . This region is significant as it lies in the N-terminal regulatory domain of CDC25A, which contains multiple phosphorylation sites involved in protein regulation and stability. The antibody has been purified by affinity chromatography using epitope-specific peptide to ensure specificity and reduced background in experimental applications . Western blot analysis has confirmed its ability to detect endogenous levels of total CDC25A protein in human and mouse cell lines, such as HeLa and 3T6 cells .

What are the validated applications for CDC25A (Ab-76) Antibody?

The CDC25A (Ab-76) Antibody has been validated for several experimental applications:

• Western Blotting (WB): Recommended dilution range of 1:500-1:1000 for detecting endogenous CDC25A protein

• Enzyme-Linked Immunosorbent Assay (ELISA): Validated for detection of CDC25A in immunoassay formats

The antibody effectively detects CDC25A in human and mouse samples, with specificity verified against endogenous expression levels . When using this antibody for Western blotting, CDC25A typically appears as a band around 70 kDa. The antibody is supplied at a concentration of 1.0 mg/mL in phosphate-buffered saline (pH 7.4, 150mM NaCl, without Mg²⁺ and Ca²⁺), containing 0.02% sodium azide and 50% glycerol for stability .

How should CDC25A (Ab-76) Antibody be stored for optimal retention of activity?

For optimal preservation of CDC25A (Ab-76) Antibody activity, long-term storage at -20°C is recommended . The antibody formulation includes 50% glycerol to prevent freeze-thaw damage, but repeated freeze-thaw cycles should still be avoided as they can progressively reduce antibody activity. For short-term use (within 1-2 weeks), the antibody can be stored at 4°C .

When handling the antibody, it's advisable to aliquot the stock solution into smaller volumes upon first thawing to minimize the number of freeze-thaw cycles. Each aliquot should be of sufficient volume for single-use applications. Always centrifuge the antibody vial briefly before opening to ensure all liquid is at the bottom of the tube and to prevent loss of material. When diluting the antibody for experimental use, use fresh, cold buffer and prepare dilutions immediately before use for optimal results.

What are the critical considerations when designing Western blot experiments using CDC25A (Ab-76) Antibody?

When designing Western blot experiments with CDC25A (Ab-76) Antibody, several critical factors must be considered for optimal results:

• Sample preparation: CDC25A is subject to rapid degradation, so samples should be collected with phosphatase inhibitors and protease inhibitors to prevent degradation during lysis.

• Loading controls: Since CDC25A expression and phosphorylation status vary throughout the cell cycle, appropriate loading controls and cell cycle synchronization may be necessary depending on the research question.

• Dilution optimization: Start with the recommended 1:500-1:1000 dilution , but optimize for your specific cell type and detection method.

• Blocking conditions: Use 5% non-fat milk or BSA in TBST for blocking, but be aware that phospho-specific detection may require BSA rather than milk (which contains phosphoproteins).

• Controls: Include positive controls (cell lines known to express CDC25A, such as HeLa or 3T6) and negative controls (CDC25A-depleted samples or competing peptide controls).

• Detection method: Choose chemiluminescent or fluorescent detection based on the sensitivity required and whether multiplexing with other antibodies is needed.

• Expected molecular weight: CDC25A has a predicted molecular weight of approximately 70 kDa , but post-translational modifications and isoforms may result in bands of different sizes.

To validate specificity, consider performing peptide competition assays or using siRNA-mediated knockdown of CDC25A to confirm band identity.

How can phosphorylation analysis of CDC25A be effectively performed using antibody-based methods?

Phosphorylation analysis of CDC25A requires careful experimental design due to the multiple phosphorylation sites and their differential effects on protein function. The following methodological approach is recommended:

• Site-specific phospho-antibodies: Use antibodies specific for known CDC25A phosphorylation sites such as S76, S79, S82, S88, and T80 . Verify antibody specificity by testing each phospho-specific antibody against wild-type CDC25A and the corresponding alanine-mutant protein by Western blotting.

• Sample preparation: Treat cells with phosphatase inhibitors immediately upon lysis. Consider using phosphatase treatments as negative controls to confirm phospho-specific signals.

• Experimental controls: Include controls to account for possible interference between adjacent phosphorylation sites. Research has shown that neither S79 phosphorylation nor substitution of alanine for serine at position 79 interferes with the ability of the phospho-S82 antibody to recognize CDC25A when it is phosphorylated on S82 . Similarly, S76 phosphorylation does not interfere with phospho-S79 antibody recognition .

• Kinase inhibitor studies: To identify the responsible kinases, use specific inhibitors in cell-based assays before immunoblotting with phospho-specific antibodies. Research indicates casein kinase 1 functions as both penultimate and ultimate kinase in the regulation of CDC25A .

• Validation methods: Employ mass spectrometry (MS) approaches as an orthogonal method to confirm phosphorylation sites identified by antibody-based methods.

• Functional correlation: Correlate phosphorylation states with CDC25A activity using phosphatase activity assays against CDK/cyclin substrates to establish functional significance.

What cell models are most appropriate for studying CDC25A function using the (Ab-76) Antibody?

The selection of appropriate cell models for studying CDC25A function using the (Ab-76) Antibody depends on the specific research questions being addressed. Based on available data:

• HeLa and 3T6 cells: These have been validated for CDC25A (Ab-76) Antibody use in Western blotting applications and express detectable levels of endogenous CDC25A.

• Cancer cell lines: Since CDC25A is frequently overexpressed in various cancers, cell lines such as Hep-3B (liver cancer), HTERT-HME1 (immortalized mammary epithelial cells), and Fem-X (melanoma) may be appropriate, as these lines have been used in CDC25 inhibitor studies .

• Synchronized cell populations: To study cell cycle-specific functions, cells synchronized at different cell cycle stages (G1, S, G2/M) using methods such as double thymidine block or nocodazole treatment can reveal the dynamic regulation of CDC25A.

• CDK2-cyclin complex models: For studying CDC25A interactions with CDK2-cyclin A complexes, in vitro reconstituted systems or cell models that allow purification of these complexes can be valuable, particularly given the recent cryo-EM structural data of the CDC25A-CDK2-cyclin A complex .

• Mouse models: The antibody cross-reacts with mouse CDC25A , making mouse-derived cell lines suitable for comparative studies between human and mouse systems.

When selecting a cell model, consider the endogenous expression level of CDC25A, the presence of functional CDK-cyclin complexes, and the integrity of cell cycle checkpoints to ensure relevance to your specific research question.

How can the CDC25A (Ab-76) Antibody be utilized to investigate the structural interactions in the CDK2-cyclin A-CDC25A complex?

Recent cryo-EM studies have revealed the detailed structure of the CDK2-cyclin A-CDC25A complex at 2.7-2.91 Å resolution , providing new opportunities for investigating these interactions using the CDC25A (Ab-76) Antibody. The antibody targets the peptide sequence around amino acids 73-77 (M-G-S-S-E) , which is in the N-terminal region of CDC25A. This region is distinct from the catalytic domain involved in the core interaction with CDK2.

For investigating structural interactions:

• Immunoprecipitation studies: The CDC25A (Ab-76) Antibody can be used for co-immunoprecipitation experiments to pull down CDC25A and associated CDK2-cyclin A complexes, followed by Western blotting to confirm interactions.

• Structure-function analysis: Since the cryo-EM structure identified a previously unobserved CDC25A C-terminal helix that is critical for trimeric complex formation , researchers can design experiments using the antibody to detect CDC25A in wild-type and C-terminal truncation mutants to correlate structural features with complex formation.

• Epitope accessibility studies: The antibody can be used to probe whether the 73-77 region undergoes conformational changes upon complex formation by comparing binding efficiency to free CDC25A versus CDC25A in complex with CDK2-cyclin A.

• Proximity ligation assays: Combining the CDC25A (Ab-76) Antibody with antibodies against CDK2 or cyclin A in proximity ligation assays can reveal in situ interactions and subcellular localization of the complex.

• Competition studies: Since sequence conservation analysis suggests CDK1/2-cyclin A, CDK1-cyclin B, and CDK2/3-cyclin E are suitable binding partners for CDC25A, while CDK4/6-cyclin D complexes appear unlikely substrates , the antibody can be used in competition binding assays to validate these predictions.

These approaches leverage the specificity of the antibody while incorporating insights from the cryo-EM structural data to advance understanding of CDC25A's role in CDK regulation.

What methods can resolve contradictory results when studying CDC25A phosphorylation states using the (Ab-76) Antibody?

Conflicting results in CDC25A phosphorylation studies using the (Ab-76) Antibody can arise from several experimental variables. The following methodological approaches can help resolve such contradictions:

• Antibody specificity validation: Since the (Ab-76) Antibody targets amino acids 73-77 (M-G-S-S-E) , which is proximal to key phosphorylation sites including S76 and S79 , determine whether phosphorylation at these sites affects antibody binding. Perform parallel experiments with:

  • Total CDC25A antibodies targeting different epitopes

  • Phospho-specific antibodies for sites near the Ab-76 epitope

  • Dephosphorylated samples (lambda phosphatase-treated) as controls

• Cell cycle synchronization verification: Since CDC25A levels and phosphorylation states fluctuate throughout the cell cycle, inconsistent synchronization can lead to contradictory results. Verify synchronization efficiency using:

  • Flow cytometry for DNA content

  • Cyclin expression patterns (Western blotting)

  • CDK activity assays as functional readouts

• Complementary techniques for phosphorylation detection:

  • Mass spectrometry to identify and quantify specific phosphorylation sites

  • Phos-tag SDS-PAGE to separate phosphorylated forms

  • 2D gel electrophoresis to resolve differentially phosphorylated isoforms

• Genetic approaches:

  • Compare phospho-mutant CDC25A (alanine substitutions) with phospho-mimetic versions (glutamic acid substitutions)

  • Use CRISPR/Cas9 to introduce specific mutations at endogenous loci

  • Employ kinase inhibitors with defined specificities to correlate kinase activity with specific phosphorylation events

• Standardized sample handling:

  • Implement consistent lysis conditions with appropriate phosphatase inhibitors

  • Standardize time from cell harvest to protein denaturation

  • Control for protein phosphatase activity during experimental procedures

By systematically applying these methods, researchers can resolve contradictory results and establish a more comprehensive understanding of CDC25A phosphorylation dynamics.

How can the CDC25A (Ab-76) Antibody be used to investigate CDC25A-specific interactions with different CDK-cyclin complexes?

The CDC25A (Ab-76) Antibody provides a valuable tool for investigating CDC25A's selective interactions with different CDK-cyclin complexes. Recent structural analyses suggest CDC25A preferentially interacts with specific CDK-cyclin pairs, with CDK1/2-cyclin A, CDK1-cyclin B, and CDK2/3-cyclin E being suitable binding partners, while CDK4/6-cyclin D complexes appear to be unlikely substrates due to sequence divergence at key interaction sites .

To investigate these specific interactions:

• Co-immunoprecipitation (Co-IP) assays:

  • Use CDC25A (Ab-76) Antibody to immunoprecipitate CDC25A from cell lysates

  • Probe immunoprecipitates for co-precipitating CDKs and cyclins

  • Compare interaction strengths across different cell cycle phases

  • Include appropriate controls: IgG control, input lysate quantification

• In vitro binding assays with purified components:

  • Express and purify recombinant CDK-cyclin complexes

  • Perform pull-down assays using immobilized CDC25A (Ab-76) Antibody

  • Quantify binding affinities using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC)

  • Create a hierarchy of binding preferences across different CDK-cyclin combinations

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS):

  • Use HDX-MS to identify regions of CDC25A that show protection upon binding to different CDK-cyclin complexes

  • Compare protection patterns between CDK2-cyclin A and other CDK-cyclin combinations

  • Correlate with cryo-EM structural data which revealed protection of CDK2 residues 196-220 (MVTRRALFPGDSEIDQLFRIFRTLG) upon CDC25A binding

• Functional phosphatase assays:

  • Measure CDC25A-mediated dephosphorylation rates of different phosphorylated CDK-cyclin complexes

  • Use the antibody to immunoprecipitate CDC25A for in vitro phosphatase activity assays

  • Correlate dephosphorylation efficiency with binding affinity measurements

• Competitive binding experiments:

  • Use fluorescently labeled CDC25A and measure displacement by unlabeled CDK-cyclin complexes

  • Determine IC50 values for different complexes to quantify relative binding strengths

  • Investigate whether binding is mutually exclusive or cooperative between different complexes

These approaches will provide insights into the determinants of CDC25A specificity across the CDK-cyclin family, which has implications for targeted therapeutic development.

What are the common technical challenges when using CDC25A (Ab-76) Antibody in Western blotting, and how can they be overcome?

Researchers frequently encounter technical challenges when using CDC25A (Ab-76) Antibody for Western blotting. Here are solutions to common problems:

• High background signal:

  • Increase blocking time and concentration (5-10% blocking agent)

  • Extend washing steps (4-5 washes of 10 minutes each)

  • Reduce primary antibody concentration (try 1:1000 or 1:2000 dilutions)

  • Use filtered buffers to remove particulates

  • Consider using different blocking agents (BSA instead of milk, or vice versa)

• Weak or no signal:

  • Increase protein loading (50-100 μg total protein)

  • Reduce antibody dilution (1:500 as recommended)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use enhanced sensitivity detection reagents

  • Verify CDC25A expression in your cell type using positive control lysates (HeLa or 3T6 cells)

  • Check protein transfer efficiency with reversible staining

• Multiple bands or unexpected band sizes:

  • CDC25A undergoes extensive post-translational modifications and may appear as multiple bands

  • Verify specificity with siRNA knockdown or competing peptide controls

  • Use phosphatase treatment of lysates to reduce phosphorylation-dependent mobility shifts

  • Consider cell cycle stage synchronization as CDC25A expression and modification vary throughout the cell cycle

• Protein degradation:

  • Always use fresh lysates when possible

  • Include protease inhibitors in lysis buffer

  • Maintain samples at 4°C throughout preparation

  • Use phosphatase inhibitors to prevent dephosphorylation events that may trigger degradation

  • Consider adding deubiquitinating enzyme inhibitors to prevent degradation via the ubiquitin-proteasome pathway

• Inconsistent results between experiments:

  • Standardize cell culture conditions, as CDC25A levels are affected by cell density and growth factors

  • Establish consistent lysate preparation protocols

  • Create aliquots of antibody to avoid freeze-thaw cycles

  • Use the same lot of antibody when possible for long-term studies

  • Include internal controls in each experiment

Implementing these optimizations should improve consistency and reliability when using the CDC25A (Ab-76) Antibody in Western blotting applications.

How can CDC25A (Ab-76) Antibody be validated for specificity in different experimental contexts?

Validating antibody specificity is crucial for ensuring reliable results. For CDC25A (Ab-76) Antibody, consider these comprehensive validation approaches:

• Genetic validation:

  • siRNA/shRNA knockdown: Compare signal between control and CDC25A-depleted samples

  • CRISPR/Cas9 knockout: Generate CDC25A-null cells as negative controls

  • Overexpression: Confirm increased signal in CDC25A-overexpressing cells

  • Mutational analysis: Test antibody recognition of the epitope region (amino acids 73-77) by creating point mutations

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide (M-G-S-S-E sequence)

  • Compare signal between competed and non-competed antibody

  • Include irrelevant peptide controls to confirm specificity of competition

• Orthogonal detection methods:

  • Compare results with other CDC25A antibodies targeting different epitopes

  • Correlate antibody-based detection with mass spectrometry identification

  • Use fluorescent protein tagging to independently track CDC25A

• Cross-reactivity assessment:

  • Test against CDC25B and CDC25C to confirm isoform specificity

  • Evaluate recognition across species (the antibody is reactive with human and mouse CDC25A)

  • Test in cells with different CDC25A expression levels

• Functional correlation:

  • Correlate detected protein levels with known CDC25A-dependent phenotypes

  • Compare antibody-detected patterns with cell cycle-dependent fluctuations of CDC25A

  • Correlate with CDK dephosphorylation status, which is directly regulated by CDC25A

• Technical validation controls:

  • Include loading controls appropriate for your experimental system

  • Use purified recombinant CDC25A protein as a positive control

  • Run samples from different cell types with known CDC25A expression

  • Test antibody across a range of concentrations to establish detection limits

By implementing these validation strategies, researchers can confidently apply the CDC25A (Ab-76) Antibody across various experimental contexts with high specificity and reliability.

How should researchers interpret variations in CDC25A protein levels detected by (Ab-76) Antibody across different cell cycle phases?

When interpreting CDC25A protein levels across the cell cycle, researchers should consider several factors that influence expression, localization, and modification state:

• Normal cell cycle fluctuations:

  • CDC25A protein levels typically increase during G1 phase and peak at G1/S transition, as CDC25A activates CDK2/cyclin E and cyclin A complexes

  • A second increase often occurs during G2/M transition when CDC25A activates CDK1/cyclin B

  • These fluctuations are primarily regulated through ubiquitin-mediated proteolysis

• Interpretation guidelines:

  • Always include cell cycle markers in your analysis (e.g., cyclin E for G1/S, cyclin A for S, cyclin B for G2/M)

  • Normalize CDC25A signal to appropriate loading controls (total protein stains may be preferable to single proteins that might fluctuate during the cell cycle)

  • Consider the phosphorylation status, as CDC25A undergoes extensive modification at sites including S76, S79, S82, S88, and T80

  • Distinguish between changes in total protein levels versus redistribution between subcellular compartments

• Checkpoint activation effects:

  • DNA damage leads to rapid CDC25A degradation as part of checkpoint activation

  • Verify checkpoint status by monitoring CHK1/CHK2 phosphorylation and p53 levels

  • Interpret changes in the context of upstream regulators (ATM/ATR pathway status)

• Technical considerations in interpretation:

  • The epitope recognized by (Ab-76) Antibody (amino acids 73-77) is near phosphorylation sites that may affect antibody binding

  • Consider using phospho-specific antibodies in parallel to distinguish between modification and degradation

  • Multiple bands may represent different phosphorylation states or splice variants

• Quantification approaches:

  • Use digital image analysis with appropriate background subtraction

  • Present data as fold-change relative to a defined cell cycle phase

  • Include statistical analysis across multiple experiments

  • Consider pulse-chase experiments to distinguish changes in synthesis versus degradation rates

By carefully controlling for these variables and including appropriate markers, researchers can meaningfully interpret CDC25A dynamics throughout the cell cycle.

What insights can be derived from the structural interaction between CDC25A and CDK2-cyclin A when interpreting experimental results?

The recent cryo-EM structure of the CDK2-cyclin A-CDC25A complex at 2.7-2.91 Å resolution provides valuable context for interpreting experimental results involving CDC25A (Ab-76) Antibody. Key structural insights include:

• Substrate specificity determinants:

  • The structure reveals that CDC25A contains a C-terminal helix that binds at the CDK2-cyclin A interface and is critical for trimeric complex formation

  • Sequence conservation analysis suggests CDK1/2-cyclin A, CDK1-cyclin B, and CDK2/3-cyclin E are suitable binding partners for CDC25A, while CDK4/6-cyclin D complexes appear unlikely substrates

  • When interpreting CDC25A-CDK interaction data, researchers should consider these substrate preferences

• Catalytic mechanism insights:

  • The cryo-EM structure shows pTyr15 of CDK2 positioned in the shallow active site of CDC25A, forming hydrogen bonds with catalytic residues including Ser431 (mutated from Cys), Glu432, Ser435, Glu436, and Arg437

  • Results showing differential dephosphorylation of CDK substrates should be interpreted considering this structural arrangement

• Functional significance of phosphorylation:

  • The structure shows that in the CDK2-cyclin A-CDC25A complex, the CDK2 activation segment containing pThr160 remains relatively unperturbed, adopting a conformation similar to that in the pT160CDK2-cyclin A crystal structure

  • This facilitates interaction with the CDC25A C-terminal helix , suggesting the importance of CDK T-loop phosphorylation for CDC25A recognition

• Interaction hotspots:

  • Hydrogen-deuterium exchange (HDX) analysis revealed significant protection of CDK2 residues 196-220 (MVTRRALFPGDSEIDQLFRIFRTLG), which include the GDSEID sequence that makes important interactions with CDC25A

  • Mutations or modifications in these regions may explain altered CDC25A-CDK interactions observed experimentally

• Interpreting mutational studies:

  • The structure identifies the CDC25A C-terminal helix as critical for complex formation

  • Experimental results showing effects of C-terminal truncations or mutations should be interpreted in this structural context

  • The conformation of the G-rich loop of CDK2 and its interaction with CDC25A provide a framework for understanding how mutations in this region affect dephosphorylation

• Cell cycle regulation context:

  • The structure suggests how CDK2-cyclin A might be preferentially recognized by CDC25A compared to other CDK-cyclin complexes

  • This provides context for interpreting cell cycle phase-specific effects of CDC25A on different CDK-cyclin complexes

By incorporating these structural insights, researchers can more accurately interpret experimental results involving CDC25A and its interactions with CDK-cyclin complexes, particularly when using the CDC25A (Ab-76) Antibody to investigate these interactions.

What emerging technologies could enhance CDC25A research using (Ab-76) Antibody in the coming years?

Several emerging technologies show promise for advancing CDC25A research in conjunction with the (Ab-76) Antibody:

• Single-cell analysis techniques:

  • Single-cell Western blotting could reveal cell-to-cell variations in CDC25A levels not detectable in population averages

  • Mass cytometry (CyTOF) with metal-conjugated CDC25A (Ab-76) Antibody would allow simultaneous measurement of multiple parameters in single cells

  • Imaging mass cytometry could provide spatial distribution of CDC25A relative to other cell cycle regulators at subcellular resolution

• Advanced microscopy approaches:

  • Super-resolution microscopy (STORM/PALM) with fluorophore-conjugated (Ab-76) Antibody to visualize CDC25A distribution at nanometer resolution

  • Lattice light-sheet microscopy for high-speed 3D imaging of CDC25A dynamics in living cells

  • Correlative light and electron microscopy (CLEM) to connect CDC25A localization with ultrastructural features

• Proximity-based interaction technologies:

  • BioID or TurboID fused to CDC25A to identify proximal proteins in living cells, complementing antibody-based interaction studies

  • APEX2-based proximity labeling for temporal control of interaction mapping

  • Split-protein complementation assays to visualize CDC25A-CDK interactions in real-time in living cells

• Structural biology integration:

  • Cryo-electron tomography to visualize CDC25A-containing complexes in their native cellular environment

  • Combining AlphaFold2 predictions with experimental structures to model CDC25A interactions with various CDK-cyclin complexes

  • Time-resolved structural techniques to capture conformational changes during CDC25A-mediated CDK activation

• Genome and protein engineering:

  • CRISPR-based endogenous tagging of CDC25A to study native protein dynamics

  • Optogenetic control of CDC25A activity or degradation for precise temporal manipulation

  • Degron-based approaches for rapid CDC25A depletion to study acute effects on cell cycle progression

• Spatial proteomics and interactomics:

  • APEX2-CDC25A fusion for proximity biotinylation to map subcellular interactomes

  • Spatial mapping of CDK-cyclin complexes relative to CDC25A using multiplexed immunofluorescence

  • Tracking CDC25A movement between subcellular compartments using live-cell imaging and photoactivatable probes

By integrating these emerging technologies with established antibody-based methods, researchers can gain unprecedented insights into CDC25A biology, potentially revealing new therapeutic targets for cancer and cell cycle-related disorders.

What are the most promising therapeutic applications emerging from CDC25A research that could be advanced using the (Ab-76) Antibody?

Recent advances in understanding CDC25A structure and function reveal several promising therapeutic directions that could be explored using the CDC25A (Ab-76) Antibody:

• Cancer therapy development:

  • CDC25A is frequently overexpressed in various cancers, making it a potential therapeutic target

  • The (Ab-76) Antibody can be used to screen and validate CDC25A inhibitors by monitoring their effects on CDC25A levels, localization, and protein-protein interactions

  • Compounds like quinones have shown activity against CDC25B and C with IC50 values of 45.5 ± 8 μM , and similar approaches could target CDC25A

• Cell cycle checkpoint modulation:

  • The antibody can help validate approaches that target CDC25A to enhance checkpoint activation in cancer cells

  • By understanding CDC25A regulation in checkpoint responses, therapeutic strategies can be developed to selectively kill checkpoint-deficient cancer cells

  • Combining CDC25A inhibitors with DNA-damaging agents might enhance therapeutic efficacy

• Structure-based drug design:

  • The recent cryo-EM structure of the CDK2-cyclin A-CDC25A complex provides a foundation for rational drug design

  • The antibody can validate whether candidate molecules disrupt key CDC25A interactions identified in the structure

  • Targeting the newly identified CDC25A C-terminal helix that is critical for CDK2-cyclin A binding represents a novel therapeutic approach

• Biomarker development:

  • CDC25A (Ab-76) Antibody could help establish CDC25A as a prognostic or predictive biomarker in various cancers

  • Correlation of CDC25A levels or modifications with treatment response could guide personalized therapy

  • Developing standardized immunohistochemistry protocols using the antibody for clinical applications

• Combination therapy strategies:

  • The antibody can help evaluate synergistic effects between CDC25A inhibitors and established therapies

  • Understanding how CDC25A status affects response to CDK inhibitors could guide rational drug combinations

  • Identifying synthetic lethal interactions with CDC25A inhibition using the antibody to monitor cellular responses

• Novel delivery approaches:

  • Developing CDC25A antibody-drug conjugates for targeted therapy

  • Creating nanoparticle formulations containing CDC25A inhibitors and using the antibody to track their efficacy

  • Exploring CDC25A-based imaging agents for cancer detection and monitoring

These therapeutic applications represent significant opportunities for translating basic CDC25A research into clinical advances, with the CDC25A (Ab-76) Antibody serving as an important tool for validation and mechanistic studies.